Dihydrofluoxymesterone

Dihydrofluoxymesterone

Clinical data
Other names	U-7265; 5α-Dihydrofluoxymesterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-dihydrotestosterone; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-DHT; 9α-Fluoro-11β-hydroxy-17α-methyl-5α-androstan-17β-ol-3-one
Routes of administration	By mouth
Drug class	Androgen; Anabolic steroid
Identifiers
CAS Number	51773-60-5^N[EPA]
PubChem CID	236179
ChemSpider	206123
KEGG	C15338
ChEBI	CHEBI:79840
CompTox Dashboard (EPA)	DTXSID50966086
Chemical and physical data
Formula	C20H31FO3
Molar mass	338.463 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O)F
InChI InChI=1S/C20H31FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h12,14-16,23-24H,4-11H2,1-3H3/t12-,14-,15-,16-,17-,18-,19-,20-/m0/s1 Key:OFGHFEJLUUXXNZ-XNMNPEGYSA-N

Dihydrofluoxymesterone (developmental code name U-7265) is an androgen and anabolic steroid (AAS) which was never marketed.[1][2][3] It was assessed in the treatment of breast cancer in women in at least one clinical study in the 1970s and showed effectiveness similar to that of other AAS.[1][2] The drug is the 5α-reduced analogue and metabolite of fluoxymesterone.[1][2][3]

See also

• Oxofluoxymesterone

References

1. Gordan, G. S. (1976). "Cancer in Man". Anabolic-Androgenic Steroids. pp. 499–513. doi:10.1007/978-3-642-66353-6_16. ISBN 978-3-642-66355-0.
2. Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 504–. ISBN 978-3-642-66353-6.
3. Kammerer RC, Merdink JL, Jagels M, Catlin DH, Hui KK (1990). "Testing for fluoxymesterone (Halotestin) administration to man: identification of urinary metabolites by gas chromatography-mass spectrometry". J. Steroid Biochem. 36 (6): 659–66. doi:10.1016/0022-4731(90)90185-u. PMID 2214783.